1. Lai CL, Wong D, Ip P, Kopaniszen M, Seto WK, Fung J, et al. Reduction of covalently closed circular DNA with long-term nucleos(t)ide analogue treatment in chronic hepatitis B. J Hepatol 2017;66:275-281.
6. Oone K, Inoue T, Kusumoto S, Ohike T, Goto T, Sato S, et al. Clinical usefulness of a newly developed high-sensitive hepatitis B surface antigen (HBsAg) assay for monitoring hepatitis B reactivation. Kanzo 2019;60:237-247.
16. European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol 2017;67:370-398.
17. WHO Guidelines Approved by the Guidelines Review Committee. Prevention of mother-to-child transmission of hepatitis B virus: Guidelines on antiviral prophylaxis in pregnancy. Geneva: World Health Organization; 2020.
18. Shimakawa Y, Veillon P, Birguel J, Pivert A, Sauvage V, GuillouGuillemette HL, et al. Residual risk of mother-to-child transmission of hepatitis B virus infection despite timely birth-dose vaccination in Cameroon (ANRS 12303): a single-centre, longitudinal observational study. Lancet Glob Health 2022;10:e521-e529.
22. Glebe D, Bremer CM. The molecular virology of hepatitis B virus. Semin Liver Dis 2013;33:103-112.
23. Kimura T, Ohno N, Terada N, Rokuhara A, Matsumoto A, Yagi S, et al. Hepatitis B virus DNA-negative dane particles lack core protein but contain a 22-kDa precore protein without C-terminal arginine-rich domain. J Biol Chem 2005;280:21713-21719.
26. Rokuhara A, Tanaka E, Matsumoto A, Kimura T, Yamaura T, Orii K, et al. Clinical evaluation of a new enzyme immunoassay for hepatitis B virus core-related antigen; a marker distinct from viral DNA for monitoring lamivudine treatment. J Viral Hepat 2003;10:324-330.
27. Maasoumy B, Wiegand SB, Jaroszewicz J, Bremer B, Lehmann P, Deterding K, et al. Hepatitis B core-related antigen (HBcrAg) levels in the natural history of hepatitis B virus infection in a large European cohort predominantly infected with genotypes A and D. Clin Microbiol Infect 2015;21:606.e1-10.
29. Seto WK, Wong DK, Fung J, Huang FY, Liu KS, Lai CL, et al. Linearized hepatitis B surface antigen and hepatitis B core-related antigen in the natural history of chronic hepatitis B. Clin Microbiol Infect 2014;20:1173-1180.
30. Suzuki F, Miyakoshi H, Kobayashi M, Kumada H. Correlation between serum hepatitis B virus core-related antigen and intrahepatic covalently closed circular DNA in chronic hepatitis B patients. J Med Virol 2009;81:27-33.
35. Wang ML, Deng R, Chen EQ, Tao CM, Liao J, Zhou TY, et al. Performance of serum HBcrAg in chronic hepatitis B patients with 8-year nucleos(t)ide analogs therapy. Clin Res Hepatol Gastroenterol 2019;43:301-309.
36. Mak LY, Hui RW, Fung J, Seto WK, Yuen MF. The role of different viral biomarkers on the management of chronic hepatitis B For special issue ‘Challenging issues in the treatment of viral hepatitis’. Clin Mol Hepatol 2023 Jan 19;doi:
10.3350/cmh.2022.0448.
37. Matsumoto A, Tanaka E, Minami M, Okanoue T, Yatsuhashi H, Nagaoka S, et al. Low serum level of hepatitis B core-related antigen indicates unlikely reactivation of hepatitis after cessation of lamivudine therapy. Hepatol Res 2007;37:661-666.
39. Shinkai N, Tanaka Y, Orito E, Ito K, Ohno T, Hirashima N, et al. Measurement of hepatitis B virus core-related antigen as predicting factor for relapse after cessation of lamivudine therapy for chronic hepatitis B virus infection. Hepatol Res 2006;36:272-276.
41. Sonneveld MJ, Chiu SM, Park JY, Brakenhoff SM, Kaewdech A, Seto WK, et al.; CREATE study group. Probability of HBsAg loss after nucleo(s)tide analogue withdrawal depends on HBV genotype and viral antigen levels. J Hepatol 2022;76:1042-1050.
42. Tada T, Kumada T, Toyoda H, Kiriyama S, Tanikawa M, Hisanaga Y, et al. HBcrAg predicts hepatocellular carcinoma development: An analysis using time-dependent receiver operating characteristics. J Hepatol 2016;65:48-56.
43. Tseng TC, Liu CJ, Hsu CY, Hong CM, Su TH, Yang WT, et al. High level of hepatitis B core-related antigen associated with increased risk of hepatocellular carcinoma in patients with chronic HBV infection of intermediate viral load. Gastroenterology 2019;157:1518-1529.e3.
44. Tseng TC, Hosaka T, Liu CJ, Suzuki F, Hong CM, Kumada H, et al. Hepatitis B core-related antigen stratifies the risk of liver cancer in HBeAg-negative patients with indeterminate phase. Am J Gastroenterol 2022;117:748-757.
47. Honda M, Shirasaki T, Terashima T, Kawaguchi K, Nakamura M, Oishi N, et al. Hepatitis B virus (HBV) core-related antigen during nucleos(t)ide analog therapy is related to intra-hepatic HBV replication and development of hepatocellular carcinoma. J Infect Dis 2016;213:1096-1106.
50. Kumada T, Toyoda H, Tada T, Kiriyama S, Tanikawa M, Hisanaga Y, et al. Effect of nucleos(t)ide analogue therapy on hepatocarcinogenesis in chronic hepatitis B patients: a propensity score analysis. J Hepatol 2013;58:427-433.
51. Hosaka T, Suzuki F, Kobayashi M, Fujiyama S, Kawamura Y, Sezaki H, et al. Impact of hepatitis B core-related antigen on the incidence of hepatocellular carcinoma in patients treated with nucleos(t)ide analogues. Aliment Pharmacol Ther 2019;49:457-471. Erratum in: Aliment Pharmacol Ther 2019;50:234-235.
53. Chen S, Jia J, Gao Y, Li H, Fang M, Feng H, et al. Clinical evaluation of hepatitis B core-related antigen in chronic hepatitis B and hepatocellular carcinoma patients. Clin Chim Acta 2018;486:237-244.
54. Hosaka T, Suzuki F, Kobayashi M, Hirakawa M, Kawamura Y, Yatsuji H, et al. HBcrAg is a predictor of post-treatment recurrence of hepatocellular carcinoma during antiviral therapy. Liver Int 2010;30:1461-1470.
55. Seto WK, Wong DK, Chan TS, Hwang YY, Fung J, Liu KS, et al. Association of hepatitis B core-related antigen with hepatitis B virus reactivation in occult viral carriers undergoing high-risk immunosuppressive therapy. Am J Gastroenterol 2016;111:1788-1795. Erratum in: Am J Gastroenterol 2016;111:1858.
56. Höner Zu Siederdissen C, Maasoumy B, Cornberg M. What is new on HBsAg and other diagnostic markers in HBV infection? Best Pract Res Clin Gastroenterol 2017;31:281-289.
61. Inoue T, Kusumoto S, Iio E, Ogawa S, Suzuki T, Yagi S, et al. Clinical efficacy of a novel, high-sensitivity HBcrAg assay in the management of chronic hepatitis B and HBV reactivation. J Hepatol 2021;75:302-310.
67. Wong DK, Inoue T, Mak LY, Hui RW, Fung J, Cheung KS, et al. A longitudinal study to detect hepatitis B surface and corerelated antigens in chronic hepatitis B patients with hepatitis B surface antigen seroclearance using highly sensitive assays. J Clin Virol 2023;160:105375.
68. Hsieh YC, Pan MH, Jeng WJ, Hu HH, Liu J, Mizokami M, et al. Serum HBcrAg and hepatocellular carcinoma in a Taiwanese population seronegative for HBsAg and Anti-HCV. Clin Gastroenterol Hepatol 2022 Jul 16;doi:
10.1016/j.cgh.2022.06.018.
71. Shimakawa Y, Ndow G, Kaneko A, Aoyagi K, Lemoine M, Tanaka Y; PROLIFICA/HBcrAg-RDT Study Group. Rapid point-of-care test for hepatitis B core-related antigen to diagnose high viral load in resource-limited settings. Clin Gastroenterol Hepatol 2022 Jun 11;doi:
10.1016/j.cgh.2022.05.026.
72. Janssen HLA, Hou J, Asselah T, Chan HLY, Zoulim F, Tanaka Y, et al. Randomised phase 2 study (JADE) of the HBV capsid assembly modulator JNJ-56136379 with or without a nucleos(t) ide analogue in patients with chronic hepatitis B infection. Gut 2023 Jan 25;doi:
10.1136/gutjnl-2022-328041.
73. Yamamoto N, Sato Y, Munakata T, Kakuni M, Tateno C, Sanada T, et al. Novel pH-sensitive multifunctional envelope-type nanodevice for siRNA-based treatments for chronic HBV infection. J Hepatol 2016;64:547-555.
74. Yuen MF, Locarnini S, Lim TH, Strasser S, Sievert W, Cheng W, et al. Short term RNA interference therapy in chronic hepatitis B using JNJ-3989 brings majority of patients to HBsAg <100 IU/ml threshold. J Hepatol 2019;70 Suppl:e51-e52.
76. Han K, Cremer J, Elston R, Oliver S, Baptiste-Brown S, Chen S, et al. A randomized, double-blind, placebo-controlled, first-timein-human study to assess the safety, tolerability, and pharmacokinetics of single and multiple ascending doses of GSK3389404 in healthy subjects. Clin Pharmacol Drug Dev 2019;8:790-801.
77. Block TM, Young JAT, Javanbakht H, Sofia MJ, Zhou T. Host RNA quality control as a hepatitis B antiviral target. Antiviral Res 2021;186:104972.
78. Mueller H, Wildum S, Luangsay S, Walther J, Lopez A, Tropberger P, et al. A novel orally available small molecule that inhibits hepatitis B virus expression. J Hepatol 2018;68:412-420.
80. Liu F, Lee ACH, Guo F, Kondratowicz AS, Micolochick Steuer HM, Miller A, et al. Host poly(A) polymerases PAPD5 and PAPD7 provide two layers of protection that ensure the integrity and stability of hepatitis B virus RNA. J Virol 2021;95:e0057421.
81. Delahaye J, Long E, Lau C, Parsons J, Wen B, Cui Z, et al. Combination treatment of a PAPD5/7 inhibitor with an antisense oligonucleotide bepirovirsen with concurrent dosing shows additive HBsAg decreases in the AAV-HBV mouse model. J Hepatol 2022;77 Suppl:S880.
86. Seto WK, Liu KS, Mak LY, Cloherty G, Wong DK, Gersch J, et al. Role of serum HBV RNA and hepatitis B surface antigen levels in identifying Asian patients with chronic hepatitis B suitable for entecavir cessation. Gut 2021;70:775-783.
88. Hoofnagle JH. A modern therapy for an ancient disease. N Engl J Med 2022;387:1996-1998.